Penumbra to Highlight Peripheral Vascular Technologies at AIMsymposium and VEITHsymposium in New York

Final Results of Indigo® System Multicenter
PRISM Trial Will Be Presented

ALAMEDA, Calif.–(BUSINESS WIRE)–
Penumbra,
Inc.
(NYSE: PEN), a global interventional therapies company, today
announced its presence at the upcoming 24th AIMsymposium®
to be held November 14-17 and the 43rd VEITHsymposium®
to be held November 15-19 in New York. Penumbra will highlight its
peripheral vascular technologies, and final results of the multicenter
PRISM study, designed to assess the safety and efficacy of the Indigo®
System for peripheral and visceral arterial thrombi and emboli, will be
presented.

The Indigo System is a novel mechanical aspiration system for the
removal of emboli and thrombi in the peripheral vasculature. PRISM,
which began in 2014, evaluated the use of the Indigo System for patients
with peripheral occlusions secondary to acute ischemia, incomplete
reperfusion and procedure-related distal emboli, using primarily the
system’s smaller size catheters. “Multicenter Retrospective Analysis Of
Results Of Penumbra Indigo System For Mechanical Clot Aspiration From
Arteries: How It Works, Indications, Vessel Sizes And Decreased Need For
Lytics: The PRISM Registry” will be presented by Dr. James Benenati of
Miami Cardiac & Vascular Institute (Florida) on Thursday, November 17,
at 4:50 p.m. in Grand Ballroom West, 3rd Floor, Session 62.

Penumbra will showcase its growing portfolio of peripheral vascular
technologies at its booth (#310 and 311 – 3rd Floor Promenade),
including its latest enhancement to the Indigo System, the Advanced
Separator, which is offered with the larger size separator and designed
to be more robust and supportive for clot extraction in larger arteries
and veins in the periphery. Penumbra will also feature its embolization
product line: Ruby® Coil, POD®, POD Packing Coil
and LANTERN®, a low-profile, high flow coil delivery
microcatheter.

Podium Presentations

Penumbra’s embolization and thrombectomy devices will be highlighted in
several podium presentations throughout the week:

  • “Use of the Indigo Device for Acute DVT: Replacing Thrombus
    Dissolution with Thrombus Extraction” will be presented by Dr. Patrick
    Muck
    of Good Samaritan Hospital (Cincinnati, Ohio) on Tuesday,
    November 15
    , at 2:30 p.m. in the Trianon Ballroom.
  • “Advantages of The Indigo Thrombectomy Device from Penumbra to Treat
    ALI – How does it Get Clot Out More Effectively: Does It Have
    Disadvantages or Limitations” will be presented by Dr. Muck on
    Wednesday, November 16, at 3:40 p.m. in the Grand Ballroom West.
  • “Why the Indigo Catheter Mechanical Thrombectomy System is A Better
    Way to Remove Clot and Debris from Blood Vessels and Decrease the Need
    for Lytic Drugs” will be presented by Dr. Frank Arko of Sanger Heart &
    Vascular Institute
    (Charlotte, North Carolina) on Thursday, November
    17
    , at 4:56 p.m. in the Grand Ballroom West.
  • “Value of Indigo Thrombus Aspiration System in Acute Limb Ischemia and
    Visceral Artery Thromboses or Emboli: Why it is a Game Changer” will
    be presented by Dr. George Adams of University of North Carolina
    Medical Center
    (Raleigh and Chapel Hill, North Carolina) on Thursday,
    November 17
    , at 5:02 p.m. in the Grand Ballroom West.
  • “Use of the LANTERN Microcatheter and Ruby and POD Coils (Penumbra)
    for Arterial Embolization: What are Their Advantages and Limitations”
    will be presented by Dr. Aaron Fischman of Mount Sinai Medical Center
    (New York) on Thursday, November 17, at 5:14 p.m. in the Grand
    Ballroom West.

Company-Sponsored Events

Penumbra will host a lunch symposium on Wednesday, November 16, at noon
at Gramercy Suite East, 2nd Floor, New York Hilton Midtown. The
symposium will include presentations on Penumbra’s peripheral vascular
technologies by Dr. Arko and Dr. Benenati.

Penumbra will also participate in hands-on workshops where physicians
can join in discussions with experienced users and utilize Indigo
System, Ruby Coil, POD, POD Packing Coil and LANTERN in simulated models:

  • Wednesday, November 16: Venous Venous Venous™ Workshops at
    VEITHsymposium, Module 2: DVT Treatment (featuring Indigo System), 1-6
    p.m.
    , Americas Hall 2, 3rd Floor
  • Thursday, November 17: AIMsymposium Workshops / Case Presentations,
    Concourse A, Concourse Level (featuring Indigo System, Ruby Coil, POD,
    POD Packing Coil and LANTERN)

    • 8-9 a.m. – PVD
    • 10-11 a.m. – Embolization
    • 11 a.m. to noon – IVC Filters
    • 2-3 p.m. – TACE / Radioembolization
    • 5-6 p.m. – Venous / Lymphatic Intervention

About Penumbra

Penumbra, Inc., headquartered in Alameda, California, is a global
interventional therapies company that designs, develops, manufactures
and markets innovative medical devices. The company has a broad
portfolio of products that address challenging medical conditions and
significant clinical needs across two major markets, neuro and
peripheral vascular. Penumbra sells its products to hospitals primarily
through its direct sales organization in the U.S., most of Europe,
Canada and Australia, and through distributors in select international
markets. Penumbra, the Penumbra logo, Indigo, Ruby, POD and LANTERN are
trademarks of Penumbra, Inc. Other trademarks are the property of their
respective owners.

Forward-Looking Statements

Except for historical information, certain statements in this press
release are forward-looking in nature and are subject to risks,
uncertainties and assumptions about us. Our business and operations are
subject to a variety of risks and uncertainties and, consequently,
actual results may differ materially from those projected by any
forward-looking statements. Factors that could cause actual results to
differ from those projected include, but are not limited to: failure to
sustain or grow profitability or generate positive cash flows; failure
to effectively introduce and market new products; delays in product
introductions; significant competition; inability to further penetrate
our current customer base, expand our user base and increase the
frequency of use of our products by our customers; inability to achieve
or maintain satisfactory pricing and margins; manufacturing
difficulties; permanent write-downs or write-offs of our inventory;
product defects or failures; unfavorable outcomes in clinical trials;
inability to maintain our culture as we grow; fluctuations in foreign
currency exchange rates; and potential adverse regulatory actions. These
risks and uncertainties, as well as others, are discussed in greater
detail in our filings with the Securities and Exchange Commission,
including our Quarterly Reports on Form 10-Q and our Annual Report on
Form 10-K for the year ended December 31, 2015. There may be additional
risks of which we are not presently aware or that we currently believe
are immaterial which could have an adverse impact on our business. Any
forward-looking statements are based on our current expectations,
estimates and assumptions regarding future events and are applicable
only as of the dates of such statements. We make no commitment to revise
or update any forward-looking statements in order to reflect events or
circumstances that may change.

Source: Penumbra, Inc.

Source: Penumbra, Inc.

Merryman Communications

Betsy Merryman, 310-560-8176

betsy@merrymancommunications.com